Schroder Investment Management Group Has $11.02 Million Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Schroder Investment Management Group trimmed its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 42.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 298,657 shares of the specialty pharmaceutical company's stock after selling 216,640 shares during the quarter. Schroder Investment Management Group owned 0.54% of Supernus Pharmaceuticals worth $11,023,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Exchange Traded Concepts LLC boosted its holdings in Supernus Pharmaceuticals by 2.6% in the 4th quarter. Exchange Traded Concepts LLC now owns 22,119 shares of the specialty pharmaceutical company's stock valued at $800,000 after purchasing an additional 560 shares during the period. HighTower Advisors LLC raised its position in shares of Supernus Pharmaceuticals by 7.3% during the fourth quarter. HighTower Advisors LLC now owns 9,130 shares of the specialty pharmaceutical company's stock valued at $330,000 after buying an additional 624 shares during the last quarter. Bridge City Capital LLC lifted its stake in shares of Supernus Pharmaceuticals by 0.8% in the fourth quarter. Bridge City Capital LLC now owns 94,997 shares of the specialty pharmaceutical company's stock valued at $3,435,000 after buying an additional 761 shares during the period. Rhumbline Advisers grew its position in Supernus Pharmaceuticals by 0.5% during the fourth quarter. Rhumbline Advisers now owns 172,444 shares of the specialty pharmaceutical company's stock worth $6,236,000 after buying an additional 800 shares in the last quarter. Finally, Swiss National Bank increased its stake in Supernus Pharmaceuticals by 0.7% during the fourth quarter. Swiss National Bank now owns 108,400 shares of the specialty pharmaceutical company's stock valued at $3,920,000 after acquiring an additional 800 shares during the period.

Remove Ads

Supernus Pharmaceuticals Stock Down 5.1 %

SUPN traded down $1.63 during midday trading on Tuesday, reaching $30.64. 641,507 shares of the company's stock were exchanged, compared to its average volume of 488,643. The business has a 50-day simple moving average of $34.09 and a two-hundred day simple moving average of $35.04. The firm has a market capitalization of $1.71 billion, a price-to-earnings ratio of 28.64 and a beta of 0.90. Supernus Pharmaceuticals, Inc. has a one year low of $25.53 and a one year high of $40.28.

Analyst Upgrades and Downgrades

A number of brokerages have commented on SUPN. Cantor Fitzgerald reiterated a "neutral" rating and issued a $36.00 price objective on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th. StockNews.com raised Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Tuesday, April 1st.

Insider Transactions at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, SVP Jonathan Rubin sold 927 shares of the stock in a transaction on Friday, February 21st. The stock was sold at an average price of $39.15, for a total transaction of $36,292.05. Following the completion of the transaction, the senior vice president now directly owns 7,853 shares in the company, valued at $307,444.95. This represents a 10.56 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Padmanabh P. Bhatt sold 9,477 shares of Supernus Pharmaceuticals stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total value of $376,236.90. Following the transaction, the vice president now directly owns 10,149 shares of the company's stock, valued at approximately $402,915.30. The trade was a 48.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 11,104 shares of company stock valued at $440,263. Corporate insiders own 9.30% of the company's stock.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.